Business News

Imfinzi/tremelimumab combo scores AstraZeneca another OS win — this time in liver cancer – Endpoints News

If anyone knows about monoclonal antibodies, it’s serial entrepreneur, Adimab CEO, and Dartmouth professor of bioengineering Tillman Gerngross.
Even the name of Gerngross’ new antibody startup Adagio Therapeutics is meant to reflect his vision behind the…

Click here to view the original article.

Related Posts

You might also like ...